COPD Drugs Market in China 2016-2020
About the Chronic Obstructive Pulmonary Disease (COPD) Drugs Market in China
Chronic obstructive pulmonary disease (COPD) is a broad term that covers progressive lung diseases, including emphysema, chronic bronchitis, refractory (non-reversible) asthma, and some forms of bronchiectasis. It restricts airflow in the lungs and is characterized by diffculty breathing. The exact etiology of COPD is not understood, but most cases are caused due to genetic factors and by inhaling pollutants, including smoke, fumes, and chemicals. As the disease develops, the symptoms tend to get worse and damages the lungs. The disease cannot be cured, and can only be managed and treated.
The COPD drugs market in China is under penetrated. It is dominated by fixed dose combinations of LABA/ICS. Air pollution is the major contributing factor for the growing prevalence of the disease. Nearly 10% of the population in the region who are over the age of 40 years has COPD. The disease is expected to become one of the leading causes of death in the country by 2020. Lack of awareness about the disease and its treatment options affects the growth of the market in this region.
Technavio’s analysts forecast the chronic obstructive pulmonary disease drugs market in China to grow at a CAGR of 15.56% during the period 2016-2020.
Covered in this report
The report covers the present scenario and the growth prospects of the chronic obstructive pulmonary disease drugs market in China for 2016-2020. To calculate the market size, Technavio considers the revenue generated from the total consumption of the chronic obstructive pulmonary disease drugs globally. The report does not include revenue generated from the aftermarket service of the product.
The market is divided into the following segments based on drug class:
• Bronchodilators
• Phosphodiesterase-4 (PDE-4) inhibitors
• Steroids
• Combination therapies
Technavio's report, Chronic Obstructive Pulmonary Disease (COPD) Drugs Market in China 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
• AstraZeneca
• Boehringer Ingelheim
• GSK
• Merck
• Novartis
Other prominent vendors
• Ache Laboratorios Farmaceuticos
• Almirall
• Aquinox Pharmaceuticals
• Ario Pharma
• BioMarck Pharmaceuticals
• Gilead Sciences
• Mereo BioPharma Group
• Mylan
• Orion
• Pearl Therapeutics
• Prosonix
• Teva Pharmaceutical Industry
• Theravance Biopharma
• Theron Pharmaceuticals
• Verona Pharma
• Xention
• ZAI Lab
Market driver
• Increase in environmental pollution
• For a full, detailed list, view our report
Market challenge
• Low diagnosis rate
• For a full, detailed list, view our report
Market trend
• Increased focus on combination therapies
• For a full, detailed list, view our report
Key questions answered in this report
• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
Chronic obstructive pulmonary disease (COPD) is a broad term that covers progressive lung diseases, including emphysema, chronic bronchitis, refractory (non-reversible) asthma, and some forms of bronchiectasis. It restricts airflow in the lungs and is characterized by diffculty breathing. The exact etiology of COPD is not understood, but most cases are caused due to genetic factors and by inhaling pollutants, including smoke, fumes, and chemicals. As the disease develops, the symptoms tend to get worse and damages the lungs. The disease cannot be cured, and can only be managed and treated.
The COPD drugs market in China is under penetrated. It is dominated by fixed dose combinations of LABA/ICS. Air pollution is the major contributing factor for the growing prevalence of the disease. Nearly 10% of the population in the region who are over the age of 40 years has COPD. The disease is expected to become one of the leading causes of death in the country by 2020. Lack of awareness about the disease and its treatment options affects the growth of the market in this region.
Technavio’s analysts forecast the chronic obstructive pulmonary disease drugs market in China to grow at a CAGR of 15.56% during the period 2016-2020.
Covered in this report
The report covers the present scenario and the growth prospects of the chronic obstructive pulmonary disease drugs market in China for 2016-2020. To calculate the market size, Technavio considers the revenue generated from the total consumption of the chronic obstructive pulmonary disease drugs globally. The report does not include revenue generated from the aftermarket service of the product.
The market is divided into the following segments based on drug class:
• Bronchodilators
• Phosphodiesterase-4 (PDE-4) inhibitors
• Steroids
• Combination therapies
Technavio's report, Chronic Obstructive Pulmonary Disease (COPD) Drugs Market in China 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
• AstraZeneca
• Boehringer Ingelheim
• GSK
• Merck
• Novartis
Other prominent vendors
• Ache Laboratorios Farmaceuticos
• Almirall
• Aquinox Pharmaceuticals
• Ario Pharma
• BioMarck Pharmaceuticals
• Gilead Sciences
• Mereo BioPharma Group
• Mylan
• Orion
• Pearl Therapeutics
• Prosonix
• Teva Pharmaceutical Industry
• Theravance Biopharma
• Theron Pharmaceuticals
• Verona Pharma
• Xention
• ZAI Lab
Market driver
• Increase in environmental pollution
• For a full, detailed list, view our report
Market challenge
• Low diagnosis rate
• For a full, detailed list, view our report
Market trend
• Increased focus on combination therapies
• For a full, detailed list, view our report
Key questions answered in this report
• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
Please Select a Format
